Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

ConclusionsDespite sound rationale and demonstrable pharmacodynamic tumor activity in relevant tumor populations, a dose and schedule could not be identified for this drug combination that was both tolerable and offered clear efficacy in the population assessed.Clinicaltrials.gov identifierNCT01392521.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research